Background:AKI is related to severe adverse outcomes and mortality with Coronavirus Infection Disease 2019 (COVID-19) patients, that early diagnosed and intervened is imperative. Neutrophil gelatinase-associated lipocalin (NGAL) is one of the most promising biomarkers for detection of acute kidney injury (AKI), but current detection methods are inadequacy, so more rapid, convenient and accuracy methods are needed to detect NGAL for early diagnosis of AKI. Herein, we established a rapid, reliable and accuracy lateral flow immunoassay based on europium nanoparticles (Eu-NPS-LFIA) for the detection of NGAL in human urine specimens. Methods:A double-antibody sandwich immunofluorescent assay using europium doped nanoparticles was employed and the NGAL monoclonal antibodies conjugate as labels were generated by optimizing electric fusion parameters. Eighty-three urine samples were used to evaluate the clinical application efficiency of this method. Results:The quantitative detection range of NGAL in AKI was 1-3000 ng/mL, and the detection sensitization was 0.36 ng/mL. The CV of intra-assay and inter-assay were 2.57%-4.98% and 4.11%-7.83%, respectively. Meanwhile, the correlation coefficient between Eu-NPS-LFIA and ARCHITECT analyzer was significant (R2=0.9829, n=83, p<0.01). Conclusions:Thus, a faster and easier operation quantitative assay of NGAL for AKI has been established, which is very important and meaningful to diagnose the early AKI, suggesting that the assay can provide an early warning of final outcome of disease.